Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Hires Swiss-Firm Lonza To Make Antibody Compounds

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and Swiss-based Lonza have formed a venture with Kyowa Hakko Kirin, which supplies Potelligent technology to Lonza, to synthesize test compounds for antibodies under development

You may also be interested in...



Mississippi Herbal ‘Parasite Removal’ Store Gets Second Warning On Claims, GMPs In Three Years

Latest warning to Humaworm notes findings that FDA inspectors made in July 2019. FDA officials apparently have been in Humaworm’s facility since then, executing a search warrant in October and confiscating encapsulating machines, herbs, capsules, computers, and records.

Torrent Outlook Muted On COVID-19, Regulatory Concerns

After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.

QUOTED. 28 May 2020. Ryan Walters.

Biotronik recently hired its first-ever chief medical officer, former Mayo Clinic medical director David Hayes, as part of a bid to deepen the Berlin-based firm’s relationships in the US. Here’s what company president Ryan Walters said about the American market.

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel